CYP19A1 and breast carcinoma: At the time of recruitment for this study, third-generation aromatase inhibitors (AIs) were the treatment of choice for postmenopausal women with newly diagnosed metastatic oestrogen receptor (ER)-positive breast cancer, either in tamoxifen-naïve patients or those progressing on adjuvant tamoxifen.